Report Overview
Reporting Period:
January 1, 2025 to December 31, 2025, with some content appropriately traced back to previous years.
Publication Cycle:
This report is an annual report and is the ninth social responsibility report released by Anhui Sunhere Pharmaceutical Excipients Co., Ltd.
Organizational Scope:
Anhui Sunhere Pharmaceutical Excipients Co., Ltd. and its subsidiaries (for organizational structure, please refer to the "About Sunhere" section of the report).
Data Sources:
The data in this report is derived from the company's official documents, statistical reports, and financial reports, and has been audited by relevant company departments.
Preparation Basis:
"Guidelines for Social Responsibility of Chinese Industrial Enterprises and Associations"
"ISO 26000: Guidance on Social Responsibility (2010)"
"Guidelines for the Preparation of Corporate Social Responsibility Reports in China (CASS-CSR2.0)"
"Guidelines for Social Responsibility of Industrial Enterprises in Anhui Province", etc.
Terminology:
For ease of expression and reading, "Anhui Sunhere Pharmaceutical Excipients Co., Ltd." is also referred to as "Sunhere", "the joint-stock company", "the company", or "we" in this report.
Preparation Process:
The Office of the Board of Directors has designated personnel responsible for the preparation of the social responsibility report, collecting information on the company's social responsibility and issues of keen interest to stakeholders, and establishing a multi-departmental report preparation team to carry out the work.
Report Access:
Anhui Sunhere Pharmaceutical Excipients Co., Ltd.
Address: No. 2, Hebin Road, Economic and Technological Development Zone, Huainan City, Anhui Province
Postal Code: 232001
Tel: 0554-2796116
Fax: 0554-2796150
Email: sunhere@shanhe01.com
You may visit the website of Anhui Sunhere Pharmaceutical Excipients Co., Ltd. at http://www.shanhe01.com/ to browse or download the report online.
Table of Contents
Chairman's Statement 1
Chapter 1 Introduction to Sunhere 2
Section 1 Corporate Overview 2
Section 2 Development History 3
Section 3 Corporate Culture 4
Section 4 Business Overview 5
Chapter 2 Corporate Governance 7
Chapter 3 Responsibility Performance 13
Section 1 Scientific Development 13
Section 2 Innovative Development 14
Section 3 Integrity Management 17
Section 4 Green Development 22
Section 5 Harmonious Development 29
Chapter 4 Responsibility Outlook and Appendix 34
Chairman's Statement
Over the past year, the state has continued to deepen the reform of pharmaceutical regulation. With the continuous advancement of centralized procurement and medical insurance reform, the industry has bid farewell to extensive growth, and quality compliance, innovation-driven development, and high quality at high prices have become the main themes of the entire industry. The regulatory system has been continuously improved, the GMP standards for the pharmaceutical excipient industry have been implemented, and the association review and pharmacopoeia standards have been continuously upgraded, putting forward higher requirements for the industry's production quality control and R&D systems. The market threshold has been further raised, and the market has accelerated its concentration towards leading enterprises with technical, quality, and supply guarantee capabilities. Facing the new situation of industry development, the company has always adhered to the "customer-centric" approach, continuously increased R&D innovation, deepened the efforts to replace imports of pharmaceutical excipients, optimized the business product structure, and focused on import substitution and overseas markets, achieving steady growth in overall operating performance.
In recent years, the company has established a relatively comprehensive social responsibility management system, upholding the core values of "growing together with employees, developing together with customers, and sharing together with society." While developing the enterprise, we work with relevant parties to promote the sustainable development of the pharmaceutical excipient industry and actively build a green, harmonious, win-win, and shared market environment.